Freeline Therapeutics Holdings plc IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Freeline Therapeutics Holdings plc | FRLN - NASDAQ |
$16.00-$18.00 | $18.00 | $18.50 | 8.8 million ADSs | 8/7/2020 |
| JP Morgan, Morgan Stanley, Evercore | ||||||
Co-Manager(s): Wedbush PacGrow | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-07-17 Terms Added 2020-08-03 | ||||||
Freeline Therapeutics Holdings plc Quote & Chart - Click for current quote - FRLN
IPO Boutique aggregates information on public companies and private companies, such as "FRLN" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Freeline Therapeutics Holdings plc (adapted from Freeline Therapeutics Holdings plc prospectus):
They are a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "FRLN" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.